StockData
ENDRA Life Sciences Inc. logo

ENDRA Life Sciences Inc. (NDRA) stock

NDRANasdaqElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 6/30
$4.04+0.12 (+2.93%)

Close on Nov 18, 2026Market cap $6.05MP/E –Yield –

Key statistics

Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026

Valuation

Market cap
$6.05M
P/E ratio
–
Price to sales
–
Price to book
0.96
Dividend yield
–
Free cash flow yield
–

Fundamentals

Net income
-$5.92M
EPS, diluted
-$5.98
Free cash flow
-$5.20M
Book value per share
$2.55
Diluted shares
2M

Trading

Previous close
$3.92
Open
$3.97
Day's range
$3.52 – $4.05
Volume
14,081
Average volume (20 days)
8,592
52-week range
$2.96 – $6.80
RSI (14 days)
32.3
Volatility (1 year)
102.9%
Relative volume
0.52×

Market cap history

Month-end market cap since 2017, using shares outstanding reported at the time

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Nov 18, 2026. The S&P 500 is measured by the SPY fund.

PeriodNDRAS&P 500DifferenceNDRA per yearS&P 500 per year
1 month-14.9%-4.3%−10.5 pts
3 months-10.5%-4.6%−5.9 pts
Year to date-10.9%+7.9%−18.8 pts
1 year-39.7%+11.8%−51.5 pts
3 years-99.8%+68.0%−167.7 pts-86.7%+18.9%
5 years-100.0%+66.2%−166.2 pts-83.9%+10.7%

Eleven years at a glance

Fiscal years 2015 to 2025 and trailing twelve months, USD

Revenue

–

Gross profit

–

Operating income

-$6.65M

Net income

-$5.92M

EPS, diluted

-$5.98

Free cash flow

–
Reported periodTrailing twelve months

Press releases

Releases ENDRA Life Sciences filed with the SEC as exhibits to Form 8-K or 6-K

All press releases and earnings

About ENDRA Life Sciences

Electromedical & Electrotherapeutic Apparatus

ENDRA Life Sciences Inc. is a medical technology company developing Thermo-Acoustic Enhanced Ultrasound (TAEUS), a non-invasive platform designed to evaluate tissue composition and assess liver fat at the point of care. The company focuses primarily on liver applications to detect and monitor metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH). Its initial liver product operates alongside conventional ultrasound systems to measure liver fat without requiring large capital equipment investments. The company targets pharmaceutical firms and clinical research organizations conducting metabolic trials, concierge primary care networks, bariatric and metabolic clinics, and broader primary and internal medicine practices.

Company profile, executives and history

ENDRA Life Sciences stock: common questions

What is ENDRA Life Sciences's stock price?

NDRA closed at $4.04 on Nov 18, 2026, up 2.93% on the day. Over the past 52 weeks it traded between $2.96 and $6.80.

What is ENDRA Life Sciences's market cap?

ENDRA Life Sciences was worth $6.05M at the close on Nov 18, 2026: the share price times the diluted shares outstanding.

What is NDRA's P/E ratio?

ENDRA Life Sciences lost money over the twelve months to Jun 30, 2026 (diluted EPS -$5.98), so it has no meaningful P/E ratio.

Does ENDRA Life Sciences pay a dividend?

No. ENDRA Life Sciences has not paid a cash dividend over the last twelve months.

How has NDRA stock performed over the past year?

Including dividends, NDRA returned -39.7% over the past year, against +11.8% for the S&P 500.

How many NDRA shares are sold short?

0M shares were sold short at the latest FINRA report, 2.98% of the float, or 2.0 days of average trading volume.

Who are ENDRA Life Sciences's competitors?

Companies most similar to ENDRA Life Sciences by business, industry and size include QTI, FOCL, ENDV, TMDX, HYPR.

See a number that looks wrong?